Ovarian cancer frequently recurs following primary surgery and combination chemotherapy. 1, 2 These relapses almost always occur within the peritoneal cavity, and frequently this is the only site of disease. In order to maximize the exposure of tumor cells to cytotoxic agents, investigators have developed intraperitoneal (i.p.) chemotherapy approaches to target i.p. ovarian carcinoma. These i.p. treatment regimens have been significantly superior to intravenous regimens in some randomized trials, but the efficacy of the approach has been limited by cancer cell resistance to standard chemotherapeutic agents. 3 Many potential mechanisms of resistance to standard chemotherapy have been explored. Predictors of relapse include clinical variables (eg residual tumor following debulking surgery) as well as molecular variables. 4 ,5 p53 mutation has been associated with an increased risk of relapse and resistance to cisplatin-based chemotherapy. [6] [7] [8] [9] [10] In addition to p53 gene mutation, cisplatin resistance can also be associated with an apparent loss of p53 function without gene mutation. [11] [12] [13] Therefore, tumor cells that have lost p53 function, regardless of the mechanism, can lead to chemotherapy resistant treatment failure.
complete regressions in 11 of 12 mice (versus one of seven controls; P = 0.001), while mice bearing cisplatin-resistant A2780 tumors had significantly improved survival versus controls (P = 0.05). In contrast, the A2780 p53(+) ovarian cancer xenograft was resistant to dl1520. The efficacy of i.p. dl1520 in the p53(−) models correlated strongly with tumor burden present at the time of treatment initiation, and no efficacy was seen with non-replicating/UV-inactivated dl1520. Selectively replicating viruses such as dl1520 hold promise as i.p. therapies for p53-deficient and chemotherapy-resistant ovarian carcinomas. A phase I clinical trial of i.p. dl1520 (ONYX-015) is underway in patients with cisplatin-resistant ovarian carcinoma. Gene Therapy (2000) 7, 1925-1929. Novel agents are, therefore, needed to eradicate chemotherapy-resistant i.p. ovarian carcinoma cells. Such agents should not show cross-resistance with standard chemotherapy (eg cisplatin and paclitaxel) and should be able to kill p53-deficient tumor cells. ONYX-015 is an E1B-55 kDa gene-deleted adenovirus that reportedly replicates in and destroys tumor cells lacking p53 function selectively.
14 Testing of matched RKO tumor cell lines Ϯ functional p53 demonstrated that p53 can inhibit the cytopathic effects (c.p.e.) and replication of ONYX-015. 14, 15 Normal endothelial and epithelial cells are relatively resistant to ONYX-015-mediated effects. 16 Controversy has arisen, however, because the p53 gene sequence alone does not predict for the efficacy of ONYX-015. [17] [18] [19] This is not surprising given the complexities of the p53 response pathway(s). In addition to gene mutation, p53 function can be lost through protein degradation (eg via mdm2 or human papillomavirus E6 protein-binding), sequestration or other mechanisms. 20, 21 Clinical trials of ONYX-015 in patients with head and neck carcinoma have documented tumor-selective replication and necrosis induction; adjacent normal tissue does not appear to replicate the virus or undergo necrosis 22, 23 (and Nemunaitis, manuscript in preparation). Therefore, despite the controversy regarding the selectivity of ONYX-015 in vitro, ONYX-015 demonstrates clear selectivity in head and neck cancer patients. Of note, ONYX-015 has shown activity against chemotherapy-resistant tumors in both preclinical and clinical studies. 16, 22, 24 Despite these findings, however, correlation of p53 function with efficacy has not been convincingly demonstrated in vivo to date. We therefore tested the sensitivity of tumor lines in vivo that were identical except for p53 status.
Intratumoral injection of ONYX-015 has resulted in antitumoral efficacy both in mice and in humans. [14] [15] [16] [22] [23] [24] However, this route of administration can be suboptimal for several reasons. First, the ability of the virus to spread within a dense solid tumor is limited by anatomical barriers such as the connective tissue and extracellular matrix that comprise the stromal tissue. Second, most tumors are either not amenable to direct injection and/or are not localized to a discrete mass at the time of treatment. Novel routes of administration are therefore needed in order to optimize the efficacy and spectrum of activity of adenoviral agents. Intracavitary administration of ONYX-015 has the potential advantage of allowing infection of multiple tumor nodules during both the initial treatment and following subsequent rounds of viral replication and release into the potential space. Treatment of disseminated tumor nodules by intracavitary administration may be optimal for cancers such as ovarian, mesothelioma and superficial bladder. Given the desperate need for treatments that are able to eradicate chemotherapy-resistant i.p. ovarian carcinoma, we investigated the utility of i.p. ONYX-015 as a treatment for ovarian carcinomatosis. Efficacy has not been previously described with replication-selective adenoviruses following intraperitoneal administration.
In order to study the correlation of p53 function and sensitivity to chemotherapy with sensitivity to ONYX-015 in vitro, c.p.e. assays were carried out on matched p53(+) and p53(−) A2780 ovarian carcinoma cells. A2780 cells (normal p53 gene sequence and function), A2780/Cp70 (cisplatin-resistant, abnormal p53 function) and A2780/Ad (doxorubicin-resistant) were tested. As predicted, the parental A2780 p53(+) ovarian line was relatively resistant to cytopathic effects and killing by ONYX-015; wild-type adenovirus destroyed the cell monolayer completely at doses that were approximately 1000-fold lower ( Figure 1 ). In contrast, A2780/Cp70 cells were approximately 100-fold more sensitive to ONYX-015 than were the A2780 parental cells (Figure 1 ). The sensitivity of the A2780/Ad cell line was also greater than the parental line. Similar results have been demonstrated using viral replication as an end-point; ONYX-015 replication is approximately 100-fold more efficient in A2780/Cp70 cells than in A2780 cells (Ganly et al, manuscript in preparation) .
Treatment with i.p. ONYX-015 starting on day 12 after inoculation of A2780/Cp70 cells (visible 5-8 mm established tumors) was associated with a reduced tumor burden compared with untreated controls on both day 16 and day 23 after tumor inoculation (approximately 40% and 80% decrease in mean tumor mass, respectively; P = 0.05 at day 23) (Figure 2 ). Survival studies in the same xenograft model demonstrated a significant survival improvement associated with ONYX-015 treatment of minimal disease (treatment starting on day 3 after cell injection, P = 0.05, log-rank test). Control mice did not survive beyond 50 days whereas three of eight treated animals were still alive after 220 days (Figure 3 ). Treatment on day 3 with UV-inactivated ONYX-015 or on day 10 (established disease) with ONYX-015 had no signifi- cant effect on survival. In situ hybridization for adenoviral DNA was performed on i.p. tumor masses 5 to 10 days after ONYX-015 treatment (n = 4). Staining of scattered individual cells (two to three cell layers deep) in tumor nodules was detected at day 10. Therefore, viral replication was superficial at these early time-points. 
u. daily for 5 consecutive days) on the survival of athymic nude mice bearing i.p. A2780/Cp70 tumors. Animals (n = 8 per group) were treated with PBS (treatment initiation on day 3), UV-inactivated ONYX-015 (day 3) or ONYX-015 (day 3 or day 10). Treatment with ONYX-015 on day 3 was associated with a significant increase in survival compared with PBS or UV-inactivated ONYX-015 control groups (P = 0.05 for both groups versus day 3 ONYX-015); treatment with ONYX-015 on day 10 did not significantly prolong survival.
Treatment with ONYX-015 on day 10 after OVCAR-3 i.p. tumor cell inoculation resulted in complete tumor eradication in 11 of 12 mice (Table 1) . Control mice treated with PBS had diffuse carcinomatosis present in all three cases, as did three of four mice treated with UVinactivated ONYX-015. The high dose (10 9 total p.f.u.) and the low dose (10 8 total p.f.u.) treatment regimens led to equivalent efficacy (Table 1) .
In contrast to the efficacy seen with ONYX-015 in the OVCAR-3 and A2780/Cp70 models, no efficacy was demonstrated in similar experiments with the ONYX-015-resistant, p53(+) A2780 tumor xenografts (data not shown). Therefore, in vitro resistance to adenovirus infection predicted for in vivo resistance to i.p. ONYX-015 treatment.
We hypothesized that the i.p. tumor mass present at the time of treatment initiation might be an important determinant of the antitumoral efficacy of i.p. ONYX-015. We studied this question in two independent tumor xenograft models (OVCAR-3 and A2780/Cp70). Treatment Treatment was initiated on day 10 following i.p. inoculation of OVCAR-3 ovarian carcinoma cells as outlined under treatment regimen. Mice were then killed on day 42 and the peritoneal cavity was inspected for the presence or absence of ovarian carcinomatosis. PBS, phosphate-buffered saline; p.f.u., plaque-forming units; UV-015, UV-inactivated ONYX-015.
Gene Therapy was initiated in the OVCAR-3 model at the following time-points after i.p. inoculation of tumor cells: 3 days (microscopic disease), 17 days (visible tumor nodules Ͻ2 mm diameter) or 31 days (multiple visible nodules Ͼ2 mm diameter). All mice were killed after 42 days and the i.p. tumor burden was assessed ( Table 2 ). All six PBStreated control mice had extensive i.p. tumor masses (2-4 mm diameter each), as did all six mice treated with ONYX-015 starting on day 31. In contrast, all 12 mice treated at the earlier time-points were completely tumorfree on inspection (Table 2) . Similarly, mice bearing A2780/Cp70 tumors had significantly improved survival if treatment was initiated 3 days after cancer cell implantation, but not if treatment was delayed for 10 days (Figure 3) . Therefore, the tumor burden at the time of treatment initiation correlated with the efficacy of i.p. ONYX-015 in two independent i.p. ovarian tumor models. Novel approaches are needed to destroy intraperitoneal, chemotherapy-resistant ovarian carcinoma cells. We have demonstrated that ONYX-015 has potential utility as an i.p. therapy for ovarian cancer. Human ovarian cancer cell lines were infected and killed in replicationdependent and p53-dependent fashion by ONYX-015 in vitro. Intraperitoneal ONYX-015 administration resulted in tumor regressions and/or improved survival of mice with ovarian carcinomatosis in two p53(−) nude mousehuman tumor xenograft models; a matched p53(+) ovarian carcinoma was resistant in vivo. These data support the hypothesis that ONYX-015 tumor selectivity is at least partially modulated by p53 function within this cell line.
Several additional factors were shown to correlate with efficacy in the i.p. model. First, significant efficacy was only seen in animals with low tumor burdens. The initial infection of tumor nodules following intraperitoneal administration was superficial compared with that seen in nude mouse-human tumor xenografts following intratumoral or intravenous administration; 15, 16, 26, 27 other groups have shown similar superficial initial virus distribution with non-replicating adenoviruses. 28, 29 This finding may at least partially explain the limited efficacy against bulky tumors. Viral replication and spread should allow deeper tumor penetration than that achieved by non-replicating vectors, but tumor nodules will ONYX-015 (10 8 p.f.u. per day) or PBS was administered into the peritoneal cavity daily for 5 consecutive days. Treatment was initiated after inoculation of cells into the peritoneal cavity on the days shown. On day 42 of the study, mice were killed and the peritoneal cavity was inspected for the presence or absence of ovarian carcinomatosis. a PBS, phosphate-buffered saline number of days following inoculation of cells into the peritoneal cavity. still become increasingly resistant as their size increases. However, efficacy may be augmented by other mechanisms in vivo (eg natural killer cells, cytokines). 30 Intraperitoneal viral therapy may therefore be most effective as adjuvant therapy in the minimal residual disease state. Approaches to increase the penetration of i.p. delivered adenovirus into established tumor nodules will also need to be explored.
Nude mouse-human tumor xenografts were used in these studies in order to study replication-dependent viral efficacy. Importantly, efficacy was only seen in mice receiving live virus; UV-inactivated virus had no efficacy. This finding suggests that efficacy was dependent upon intratumoral virus replication and/or late gene expression. Since murine cells do not support efficient replication and spread of human adenoviruses, syngeneic, immunocompetent tumor models are generally not useful for testing replication-competent adenoviruses. The impact of T cell-dependent antibody and cellular immune responses may therefore need to be determined in patients, or replication-permissive syngeneic tumor models must be identified. Future studies will be needed to elucidate more clearly the antitumoral mechanisms involved. If these mechanisms can be identified and/or viral replication can be enhanced, the antitumoral efficacy of selectively replicating adenoviruses may be improved.
Replication-selective adenoviral agents clearly have promise as intraperitoneal treatments for ovarian carcinomatosis. In addition to single agent efficacy, combinations with chemotherapy may increase the efficacy of i.p. adenoviruses over that seen with either chemotherapy or virus alone. 16, 24 Based on these preclinical results, a phase I dose escalation trial of i.p. ONYX-015 is underway in patients with cisplatin-resistant, relapsed ovarian carcinoma. Selectively replicating adenoviruses, as well as other viral agents, 31, 32 have potential as therapies for ovarian carcinomatosis and other intracavitary malignancies.
